Cargando…

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations

Mostrar otras versiones (1)

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the progression of chronic kidney disease (CKD). These agents prevent decline in kidney function through reduction in glomerular hypertension mediated through tubuloglomerular feedback independent of their effect on glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yau, Kevin, Dharia, Atit, Alrowiyti, Ibrahim, Cherney, David Z.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263228/ https://www.ncbi.nlm.nih.gov/pubmed/35812300 http://dx.doi.org/10.1016/j.ekir.2022.04.094

Ejemplares similares

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

Preventing CKD in Developed Countries
por: Luyckx, Valerie A., et al.
Publicado: (2019)

DAPA-CKD: The Beginning of a New Era in Renal Protection
por: Cherney, David Z.I., et al.
Publicado: (2021)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
por: Li, Ning, et al.
Publicado: (2022)

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2023)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
por: Hosokawa, Yusei, et al.
Publicado: (2020)

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022)

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy
por: Neuwirt, Hannes, et al.
Publicado: (2019)

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
por: Liu, Hongyan, et al.
Publicado: (2021)

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Knowledge and practice of community pharmacists towards SGLT2 inhibitors
por: Alqudah, Abdelrahim, et al.
Publicado: (2022)

Obesity Indices and the Risk of CKD
por: Tsuboi, Nobuo
Publicado: (2021)

A Review of Residual Kidney Function in Peritoneal Dialysis Patients
por: Alrowiyti, Ibrahim Mohammed, et al.
Publicado: (2023)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
por: van Poelgeest, Eveline P., et al.
Publicado: (2023)

Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?
por: Cupisti, Adamasco, et al.
Publicado: (2020)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Toric intraocular lenses: Expanding indications and preoperative and surgical considerations to improve outcomes
por: Singh, Vivek Mahendrapratap, et al.
Publicado: (2022)

Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
por: Klopfenstein, Mitchell, et al.
Publicado: (2015)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_44idrnlahon37s5dbr406icdsu